OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

"Gene therapy specialist Oxford Biomedica said it's full-year pretax loss narrowed to 17.7m versus 19.4m last time.

This left it with a cash position at the end of its financial year of 38.1m versus 28.5m last time.

The company said that it has completed the recruitment of a Phase III study in renal cancer for its lead drug TroVax, which is being developed along with Sanofi-Aventis.

The trial completion is seen as a key indicator of the potential of the drug. Brokerage KBC Peel Hunt pointed out before the results that, in conjunction with a successful Drug Safety Monitoring Board review, this could be seen as an indication of effectiveness, because the FDA board could have asked the company to increase the number of trial participants. "


If trovax is successful, this is a sure multi-bagger!! and thats without Prosavin, Lentivectors and the stream of other in research. But I don't think OXB will be able to remain independant for that long, they are bound to be taken over by someone like Sanofi or Glaxo.

The broadcast will be very positive - don't forget to tune in..

Panmure Gordon said in a note to clients: 'Oxford BioMedica reported financial results better than our expectations, and also provided an update on timelines for key product candidates that are also better than our, and market, expectations. We expect the stock to be positive and reiterate our Buy recommendation.'

The interesting thing about the financials too is that 19m of Sanofi's milestone paymts which have been paid and non refundable have been held over to next yrs profits so in fact the net profit position (as is cash flow) is actually positive isn't it.

robstuff
Yes all looks OK still holding.

good tactical move .... payment prob received after formal y/e and could, had OXB, prob have been included but would have given a tougher target necxt year .... this gives a good starter for 10!

Frankly I'm surprised any "holding-over" policy exists ( at OXB)...
- if a payment is received it must be included. Such "cooking policy" is the Mark of a small outfit trying desperately to make EBITA figures look exciting - OXB investors await the outcome of the Trials, anticipated in 9 months', so plenty off time to pick up stock ( if you want) at lower prices, - like this summer, when folks are away on their Hols.
+Does anyone really follow the words of PG? - surely a minor Broker, more suited to sub-AIM stock?

hangon - what price are you hoping to get in at? ;-)

interesting - some big 1m purchases

At least the Pru have confidence in OXB with 68m shares now or 12% of OXB!

can't work out whether that is Pru or M&G .... i know i am very thick, but it reads most confusingly

Both, M&G as you probably know is a wholly owned subsidiary of the PRU.

i know nothing!

Time for some more refreshing honesty, lets have it elsewhere cynic!!

my views are always honest even if unpalatable to some, and i am always happy to be shot down by others where i am proved wrong .... the odd plaudit when proven right (surprisingly often) would also not go amiss

what a load of crap! not you cynic, the sp

forgiven - lol!

positive trial news for Trovax re Prostate cancer today!! Trovax is looking to be extremely versatile with enormous potential, the value could be Billions pa in commercial development IMO.

A small bit in the D/Mail today explaining yesterdays rise.

As with Cynic's ORE: OXB looks like it's had a similar dose of Viagra today, if not a dose of its own medicine Trovax

We think alike Toya. About to say the same thing. Some interest in this today.

Decided to take a punt based on weakness of sp.

Mind you, it could be because I hold at a higher price lol